Endocrine Society GUIDELINES Bundle (free trial)

Menopause

Endocrine Society GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1140187

Contents of this Issue

Navigation

Page 3 of 19

Diagnosis 4 Table 1. Definitions of Spectrum of Menopause Term Definition Menopause Clinical status aer the final menstrual period, diagnosed retrospectively aer cessation of menses for 12 mo in a previously cycling woman and reflecting complete or nearly complete permanent cessation of ovarian function and fertility. Spontaneous menopause Cessation of menses that occurs at an average age of 51 y in the absence of surgery or medication. Menopausal transition (or perimenopause) An interval preceding the menopause characterized by variations in menstrual cycle length and bleeding pattern, mood shis, vasomotor and vaginal symptoms and with rising FSH levels and falling anti-Mullerian hormone and inhibin B levels, which starts during the late reproductive stage and progresses during the menopause transition. Climacteric e phase in the aging of women marking the transition from the reproductive phase to the nonreproductive state. is phase incorporates the perimenopause by extending for a longer variable period before and aer the perimenopause. Climacteric syndrome When the climacteric is associated with symptomatolog y. Menopause aer hysterectomy without oophorectomy Spontaneous cessation of ovarian function without the clinical signal of cessation of menses. Induced menopause Cessation of ovarian function induced by chemotherapy, radiotherapy, or bilateral oophorectomy. Early menopause Cessation of ovarian function occurring between ages 40 and 45 in the absence of other etiologies for secondary amenorrhea (pregnancy, hyperprolactinemia, and thyroid disorders). Primary ovarian insufficiency (POI) Loss of ovarian function before the age of 40 y with waxing and waning course and potential resumption of menses, conception, and pregnancy. e prevalence of POI is approximately 1% and is differentiated into idiopathic, autoimmune (associated with polyglandular autoimmune syndromes), metabolic disorders, and genetic abnormalities (including fragile x premutation).

Articles in this issue

Archives of this issue

view archives of Endocrine Society GUIDELINES Bundle (free trial) - Menopause